Introduction
The pharmaceutical product ranibizumab is a monoclonal antibody product which is produced in the US by Genentech and sold by Novartis (under the trademark Lucentis) in Europe (including the UK). It has widely been reported that sales of this pharmaceutical generated around $1.5 billion in sales for Novartis last year. It is sold for the treatment of age-related macular degeneration, a condition in which abnormal blood vessel proliferation causes retinal damage. It binds to and interferes with the action of the protein VEGF, which has a role in the disease process.
Subject Matter of the Patents
The Patents relate to a technique called phage display. The technique as claimed was developed in order to identify antibodies with desired binding properties. Antibodies are proteins and a key characteristic of antibodies is their ability to recognise and to bind specifically to other proteins (termed antigens). Before the Patents, it was already well established that molecular biology techniques could be used to cause bacteria to produce foreign (or exogenous) proteins and that it was possible to create "libraries" of bacteria, where a population of bacteria produced large numbers of different proteins. Screening these libraries allowed one or more proteins having desired characteristics to be identified from the large number of different proteins present. The screening could be carried out based on the ability of the protein to perform a particular function or (more usually) on the ability of the protein to bind to another protein, such as an antibody. By identifying the bacteria that produced the desired protein, the relevant DNA encoding the desired protein could then be isolated, characterised and used further, e.g. to produce the desired protein in large quantities.
"Phage display" techniques were subsequently developed and these were revolutionary. Briefly, this technique uses filamentous bacteriophage (a type of virus that infects bacteria) or phagemids (which are vectors, i.e. molecular biology tools, that under appropriate conditions allow bacteria to produce filamentous bacteriophage) to produce the libraries. In such a phage display library, the proteins of potential interest are displayed on the outside surface of bacteriophage, and the DNA encoding the protein displayed by the bacteriophage is found in the DNA contained within the bacteriophage. A library of bacteriophage can thus display many thousands of different proteins. Those bacteriophage expressing a desired protein are identified on the basis of the ability of the displayed protein to bind to a target molecule. By mixing the bacteriophage with a solid support to which the target molecule is attached, the bacteriophage of interest may be physically separated from the remaining phages. The encoding DNA can then be isolated.
Before the Patents, these phage display libraries had been used to display small proteins on the surface of bacteriophage, and screening was in general carried out using an antibody (bound to the fixed support) as the target molecule. In contrast, the Patents concern techniques involving the display of antibody fragments on the surface of the bacteriophage and screening using antigen bound to the solid support. Importantly, antibody fragments are much larger proteins than those which had previously been displayed on the surface of bacteriophage.
Claim 5 of 511 is set out below:
A method for producing a filamentous bacteriophage particle displaying at its surface a binding molecule specific for a particular target epitope or antigen, which method comprises the steps of: producing a population of filamentous bacteriophage particles displaying at their surface a population of binding molecules having a range of binding specificities, wherein the binding molecules are Fab antibody molecules able to bind target epitope or antigen, and wherein each filamentous bacteriophage particle contains a phagemid genome comprising nucleic acid with a nucleotide sequence encoding the binding molecule expressed from the nucleic acid and displayed by the particle at its surface; selecting for a filamentous bacteriophage particle displaying a binding molecule with a desired specificity by contacting the population of filamentous bacteriophage particles with a target epitope or antigen so that individual binding molecules displayed on filamentous bacteriophage particles with the desired specificity bind to said target epitope or antigen." Claims 6 and 7 claim the method of claim 5, adding the steps of "separating" and "recovering" (respectively) the phage particle with the desired binding properties.
Claim 8 of 511 is directed to "8. A method for producing a binding molecule specific for a particular target epitope or antigen, which method comprises:
performing the method according to claim 7;
isolating from separated filamentous bacteriophage particles recovered according to the method of claim 7 nucleic acid encoding the binding molecule; inserting nucleic acid encoding the binding molecule, or a fragment or derivative thereof with binding specificity for the target epitope or antigen, in a recombinant system; and producing the binding molecule, or fragment or derivative thereof with binding specificity for the target epitope or antigen, in the recombinant system separate from filamentous bacteriophage particles." Claim 1 of 777 reads "1.
A method for producing a molecule with binding specificity for a particular target, which method comprises: producing a population of filamentous bacteriophage particles displaying at their surface a population of binding molecules having a range of binding properties, wherein the binding molecules comprise antibody antigen binding domains for complementary specific binding pair members, wherein the binding molecules are displayed at the surface of the filamentous bacteriophage particles by fusion with a gene III protein of the filamentous bacteriophage particles, and wherein each filamentous bacteriophage particle contains nucleic acid encoding the binding molecule expressed from the nucleic acid and displayed by the particle at its surface; selecting for a filamentous bacteriophage particle displaying a binding molecule with a desired binding property by contacting the population of filamentous bacteriophage particles with a particular target so that individual binding molecules displayed on filamentous bacteriophage particles with the desired binding property bind to said target; separating bound filamentous bacteriophage particles from the target; recovering separated filamentous bacteriophage particles displaying a binding molecule with the desired binding property; isolating nucleic acid encoding the binding molecule from separated filamentous bacteriophage particles; inserting nucleic acid encoding the binding molecule, or a fragment or derivative thereof with binding specificity for the target, in a recombinant system; and producing in the recombinant system separate from filamentous bacteriophage particles a molecule with binding specificity for the target, wherein the molecule is said binding molecule or a fragment or derivative thereof with binding specificity for the target."
The Skilled Team
The Judge devotes some time in the judgement to discussing who would be considered to be the skilled addressee of the Patents. In the case of these two Patents it was clearly a team, but the two parties disagreed as to its composition. Novartis put forward the argument that the skilled team was a team of scientists with differing backgrounds in various areas, but with a common interest in antibody engineering. MedImmune envisaged a team consisting of an immunologist and a molecular biologist, lead by the immunologist, and possibly also including a biochemist. The Judge referred to Schlumberger Holdings Ltd v Electromagnetic Geoservices AS 2 and Dyson Appliances Ltd v Hoover Ltd 3 and noted from these judgements that it is important to have regard to what skills real research teams in the art had at the time.
There was considerable factual evidence of what such a skilled team might look like. Reference was made for example to the MRC's strategy, conferences that were taking place, the commercial enterprises in the field and even the descriptions of job advertisements at the time, which were all consistent with the existence of real research teams in the field of the Patent having an interest in the field of antibody engineering, as suggested by Novartis. The Judge was, however, careful to point out that these real teams would include inventive people, whereas inventive step is judged from the view of a person or team who is deemed to lack inventive capacity.
The Preparation of Experts' Reports in Patent Cases
The judgement also discusses the preparation of experts' reports in Patent cases and emphasises that lawyers instructing experts have the responsibility of ensuring that the experts are instructed correctly to preserve the independence and impartiality of their opinions. The Judge noted that there were deficiencies in the way that the experts' reports had been prepared and presented, and emphasised the need for lawyers to provide adequate guidance to the experts so that the value of these reports to their clients' case is maximised.
Particular emphasis was made of the need to discuss prior art in full and not to omit discussion of ambiguous points or those that do not support the client's case. The expert should also disclose any relevant contributions that they have made to the scientific field in question, whether this is in the form of publications or Patent applications of their own.
Priority
Priority was claimed from five earlier applications. MedImmune accepted that the Patents were invalid if they were not entitled to claim priority from the third of these applications (PD3). Neither party had identified (and Novartis had not relied upon) any prior art made available to the public between the first and third priority date, so it was only necessary to consider the entitlement of the claims to the third priority date.
Novartis raised two objections: firstly that PD3 did not disclose the claimed invention and secondly that MedImmune were not entitled to claim priority from PD3. The second issue was not discussed in the judgement, but is to be tried separately at a later date.
In relation to the first objection, the parties agreed that the relevant principles for determining priority entitlement were as set out in Intervet UK Ltd v Merial 4 The two questions to be considered in relation to 511 were (i) whether PD3 disclosed the use of a phagemid (as required by claim 5 of 511) in itself, and (ii) whether it disclosed the use of a phagemid to display a Fab fragment (a type of antibody fragment containing specific portions of antibody molecules). As regards question (i) PD3 focussed almost entirely on the use of bacteriophage, rather than phagemid, and there was a single passage in Example 1 of PD3 that mentioned the possibility of using alternative constructions. The precise meaning of this passage was disputed MedImmune argued that it contained a disclosure of the use of phagemid as an alternative to bacteriophage. Expert evidence was considered in deciding how to interpret the passage but the Judge dismissed comments and arguments that focussed on an overly linguistic analysis and repeatedly emphasised that the skilled team, to whom PD3 was addressed, would consider the passage so as to make technical sense of it. Interpretations proposed by the experts which were inconsistent with this approach were thus disregarded, which led to MedImmune's interpretation that phagemid were disclosed being preferred. The use of a phagemid to express Fab fragments (question (ii) above) was, however, not considered to be disclosed by PD3. In that respect MedImmune argued that Example 7, which disclosed the production of a Fab fragment (but not using a construct in accordance with the claims), disclosed the relevant combination when it was read in light of the single (controversial) passage in Example 1. An alternative to the specific construct of Example 7 was also disclosed in PD3, and the skilled team would appreciate that a construct for a Fab fragment in accordance with the claim could be used. The Judge made it clear that it was not enough to establish entitlement to priority that the skilled team would consider it obvious to do something which is not directly disclosed (as set out in Abbott Laboratories Ltd v Evysio Medical Devices plc 5 ). On this basis, the Judge found that PD3 does not clearly and unambiguously disclose the combination of phagemid and Fab fragments and claims 5 to 8 of 511 were thus not entitled to priority date 3.
The above issues were specific to 511, but Novartis put forward a further argument relevant to both Patents. The term "derivative", found in each of claim 8 of 511 and claim 1 of 777 was not defined in PD3, but a definition was provided in the Patents (i.e. the definition was added after PD3). Novartis argued that the absence of any definition of this term in PD3 and the inclusion of a definition in the Patents as filed, in itself resulted in the disclosure being broadened in the Patents. This argument was rejected. Novartis also argued that the disclosure of the Patents covered methods that extended beyond methods disclosed in PD3 in that specific additional steps of recovering the DNA and carrying out "affinity maturation" (mutagenesis of the binding molecule and further selection based on the binding properties of the mutated binding molecule) were encompassed in the claims but not in the disclosure of PD3. MedImmune contended that the skilled team would understand that "derivative" as used in PD3 could be a mutated derivative and that the generation of derivatives could take place after phage display. They referred to three passages in PD3 in support of this argument. Having examined these disclosures, the Judge noted that when read in context they did not support MedImmune's assertion. He further noted that MedImmune's expert had "failed to distinguish between the message which would be conveyed by PD3 to a skilled team who had not seen the Patents from the message conveyed by the Patents." (paragraph [342]).
Consequently, it was found that post phage display mutation of antibodies as referred to in the claims of each of 511 and 777 was not disclosed in PD3 and that the relevant claims were not priority entitled. The Patents were therefore invalid.
Inventive step
Although the finding in relation to priority (by MedImmune's own admission) rendered both Patents invalid, the obviousness attack was considered in full, applying the approach established in Pozzoli v BDMO SA 6 (a reformulation of the classic Windsurfing test).
Two pieces of prior art were considered. The first was a published scientific paper (Parmley and Smith   7 ), over which the inventions as claimed were found to be not obvious. The second was a talk given by Professor Smith (an author on Parmley and Smith), given at a conference in Banbury in 1990. Both disclosures were before the first priority date and therefore available as prior art irrespective of whether the Patents were priority entitled. The Judge at the outset defined the core inventive concept "as a method consisting of two steps: (i) producing a population of phage particles displaying at their surface binding molecules having a range of binding specificities wherein each particle contains nucleic acid encoding the binding molecule; and (ii) selecting particles displaying a binding molecule with a desired specificity by contacting the population of particles with a target epitope or antigen to which the binding molecule of interest binds." (paragraph [380] ). He noted further that it was likely that skilled teams in the field of antibody engineering were aware of phage display, which was an established, although not yet routine, technique at the relevant date. He further noted (in line with the disclosure in PD3 and the Patents themselves) that there was a need for improvements to known techniques for screening for antibodies and that there were relatively few other potential solutions to the problem available at the time.
Parmley and Smith disclosed methods involving expressing antigen fragments using a "fusion" phage, in which antigens are expressed as part of a fusion protein with the gene III phage coat protein which is displayed on the phage surface. Importantly there was a statement that the method was recommended only for small protein fragments (encoded by 100-300 base pairs, which is much smaller than antibody fragments as used in the claimed method). The Judge considered evidence as to the size of antibody fragments, (which exceeded the recommended range of Parmley and Smith) and the expected effects of using such larger fragments on infectivity of the particles, breakdown of the recombinant gene III protein and the ability of antibody fragments to fold correctly when expressed in these fusions. He found in light of this that Parmley and Smith would not provide the skilled team with a reasonable prospect of success of phage display of antibody fragments.
The content of the oral disclosure by Professor Smith (who also gave evidence at the trial) at the Banbury conference was documented in his witness statement. When giving evidence, he confirmed that he had a good recollection of the talk and also that he had kept some notes and slides that he had used. The evidence showed that the talk went further than his earlier publication (Parmley and Smith) in that it explicitly suggested that phage display "might be useful in screening an antibody library with antibody displayed on pIII and antigen on the plate" (paragraph [364]), providing a slide showing how this would work. He had indicated that his group was going to carry this work out with a single chain antibody (SCA) and that if it worked it could be used to identify SCAs from a library. He had noted in his talk that there would be possible issues of folding, degradation and infectivity but had provided some possible solutions to the folding and infectivity problems, and had noted that degradation may in fact assist the method. He had mentioned the possibility of carrying out "affinity maturation" of an isolated SCA and set out two approaches to making appropriate libraries. In giving his evidence he acknowledged that he had been encouraging others to try the technology as he had thought that it would work, but that he had recognised that there would be challenges.
The Judge noted in paragraph [411] that "there can be no serious dispute that Professor Smith's talk made it obvious to try phage display of antibodies provided that there was a sufficient expectation of success having regard to the other factors considered above. The only question is whether it would have given the skilled team a reasonable expectation of success within a reasonable time." The issue of "a reasonable expectation of success within a reasonable time" was explored in some detail and expert evidence on this point was considered, which led the judge to conclude that such reasonable expectation would have arisen from Professor Smith's talk.
Secondary evidence based on Professor Smith's own work was submitted by MedImmune as evidence that there was no reasonable prospect of success within a reasonable time. This included evidence that Professor Smith thought that the project was "substantial, lengthy and speculative" (paragraph [427] ), that Professor Smith had acknowledged that there were concerns with the techniques, that he was disappointed with some of the results and the fact that he had not pursued the work further. MedImmune also submitted evidence of others' reactions to the invention, whereas Novartis' evidence was of who had had the same idea at around the same time.
The secondary evidence did not affect the Judge's view that the invention as claimed was obvious over Professor Smith's talk. Interestingly, he noted that the Opposition Division of the EPO had rejected arguments that another member of the Patent family was obvious over the same disclosure but also that different evidence had been put forward in the EPO proceedings. Specifically, the Opposition Division had not heard from Professor Smith. The Judge noted that it was common ground that the claims in question were "method claims of fairly broad scope" (paragraph [485] ) and hence the issues to be addressed were more aligned
with Biogen Inc v Medeva plc or Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, than with Generics (UK) Ltd v H. Lundbeck A/S.
After an extensive summary of the case law, the judgement considers Novartis' arguments. These were that the technical contribution of the claims is limited to only a portion of the methods as claimed (the step of screening an antibody library by phage display) and that nothing is taught in the Patent about other portions of the methods as claimed (such as the steps of identifying a target, making the antibody library, improving the binding properties of the antibodies by mutation, recombinant synthesis of the resultant mutants). These were dealt with quickly by simply confirming MedImmune's argument that the invention as disclosed is a principle of general application. The Judge noted that the identity of the binding molecule was not important, and that the broad application of the technique was part of its usefulness. The insufficiency attack thus failed.
Added Matter
There was a single issue to consider in relation to added matter; whether claim 1 of 777 and claim 5 of 511 represented an "intermediate generalisation" (as defined by Pumfrey J in Palmaz's European Patents 15 ) in view of the fact that the claims as filed did not specify that either the fragments/derivatives of the Fab or the binding molecule that are produced have binding specificity for the target epitope or antigen, whereas this is a requirement of the relevant granted claims. The Judge found that a single passage of the application as filed provided adequate basis for this subject matter, in combination with a definition in the application as filed. The added matter attack thus failed.
Infringement
Ranibizumab was developed by Genentech from a mouse monoclonal antibody specific to VEGF by eleven steps including "humanising" the antibody (to enable its administration to humans) and insertion of the encoding DNA sequences for the antibody into a phagemid vector containing a fragment of the gIII gene, such that the heavy chain was fused to the gIII protein product and the light chain was expressed in the periplasm in soluble form. Various rounds of mutagenesis and phage display were then carried out. Once a clone having desired properties was obtained, the sequence of this clone was used to make a production vector, used by Genentech to produce ranibizumab.
Novartis sells Ranibizumab in Europe.
MedImmune alleged infringement of the process claims under section 60(1)(c) of the UK Patents Act 1977 on the basis that ranibizumab is a product obtained directly from the processes of claim 8 of 511 (which in turn refers to the method of claim 5) and claim 1 of 777. Only section 60(1)(c) was available to MedImmune as no antibody product claims were present in either of the Patents and ranibizumab was made outside the UK.
The Judge firstly considered whether ranibizumab was made by a process according to the claims. With respect to claim 5 of 511, Novartis contended that two requirements of the claim were not met by Genentech's process. Genentech started their process with an antibody that was specific to the antigen of interest. The phage display technique was used to obtain an antibody with improved binding to the antigen and their process did not produce a population of particles having "a range of binding specificities" (as required by the claim). The Judge construed the phrase "a range of binding specificities" to include a range of specificities to different antigens, but to exclude a range of affinities to a single antigen, on the basis of the deliberate choice of the word "specificity", rather than "affinity" in the claim and the consistent and distinct use of these two terms throughout the Patents.
Novartis also argued that Genentech did not produce particles "each" of which contained a phagemid genome encoding the binding molecule displayed at its surface. The meaning of the term "each" was contested by the parties, who disagreed as to whether the use of this word effectively excluded methods using conventional helper phage (as used by Genentech) from the claim scope. Although he noted that the arguments were "quite finely balanced" (paragraph [301]), the Judge considered Novartis's position that only gene III deletion helper phage and not conventional helper phage were encompassed by the claims to be persuasive in view of the repeated references in the Patents to the advantages and significance of the gene III deletion helper phage in the invention.
On the basis of the above construction of the terms in claim 1, the Judge found that the process for the production of ranibizumab did not fall within the scope of the claims of 511.
The above point concerning the term "each" applied equally to claim 1 of 777. Novartis also argued that the words "a gene III protein" in this claim should be interpreted as including only a complete, or at least substantially complete, gene III protein, and as excluding the fragments of gene III proteins used by Genentech to produce fusions with the relevant antibody fragment.
The Judge preferred the narrow construction advocated by Novartis on the basis of the "natural understanding" of the skilled team and on the basis that the skilled team would know that for example C terminal fragments of the protein would not work in phage (phage being the focus of 777). The skilled team would thus consider the claim to exclude gene III protein fragments and thus Genentech's process was found to be outside the scope of claim 1 of 777.
Despite finding that Genentech's process fell outside the scope of the claims, the Judge considered the question of whether ranibizumab was a product obtained directly by the claimed process. An analysis of the relevant case law, in particular the Court of Appeal decision in Pioneer Electronics Capital Inc v Warner Music Manufacturing Europe GmbH 16 was provided. Notably the Judge indicated in paragraph [539] that this case had decided that "a product could be obtained directly from a claimed process despite further processing provided that there was no loss of identity, there being no such loss where it retained its essential characteristics". In contrast Pumfrey J had interpreted this case somewhat
differently in Halliburton Energy Services Inc v Smith International (North Sea) Ltd

17
, where he had contended that it excluded the possibility of further processing.
The Judge also discussed Monsanto Technology LLC v Cargill International SA 18 in which it had been found that ground soymeal did not infringe method claims directed to producing genetically transformed plants, as the soymeal could not be described as the direct product of the claimed method of transforming plants (in direct contrast to the original transformed plant).
According to the judgement, Counsel for Novartis accepted that although ranibizumab could be described as a product obtained directly by the process of claim 8 of 511 and claim 1 of 777 if the loss of identity test of Pioneer v Warner was applied (but presumably only if Genetech's process was indeed within the claim scope as construed), the present case should be distinguished therefrom as claim 8 of 511 was narrower than claim 5 in the sense that it requires the presence of more features before a process falls within it. If, as in this case, a broad independent claim was not infringed (and indeed, ranibizumab was not alleged to infringe claim 5), it was inconsistent for there to be a finding of infringement for a narrower subsidiary claim, particularly where the invention, if any, lies within claim 5, and where the additional steps of the subsidiary claim are only routine manufacturing steps. For claim 1 of 777 Novartis argued that ranibizumab is not a product obtained by the process of the steps in the claim that are the inventive steps. It is only as a result of the inclusion of further non-inventive manufacturing steps in the claim that infringement is able to be alleged. Thus, Novartis had argued that it was not right to apply the loss of identity test without qualification. Instead the test which should be applied is to focus on the inventive claim (or inventive part of the claim) and ask whether the allegedly infringing product is obtained directly from that process.
Although the Judge described this argument as "attractive", he noted that he was bound by Pioneer v Warner and that the loss of identity test set out therein is "a general test stated without qualifications" (paragraph [547] ). He further noted that "there is nothing inherently objectionable about affording MedImmune a remedy in this country given that ranibizumab is sold here" (paragraph [548] ). He thus concluded that "if ranibizumab was produced by a process falling within claim 8 of 511 and claim 1 of 777, it would be a product obtained directly by means of that process. On that hypothesis, Novartis would have infringed those claims subject to its argument based on the Biotech Directive."
Infringement Under the Biotech Directive
Novartis put forward an argument that the Biotech Directive precluded infringement of the process claims by referring to Article 8(2), which, they argued, applied to the Patents and had the effect that Novartis' sales of ranibizumab did not infringe. Article 8(2) of the Biotech Directive states that "The protection conferred by a Patent on a process that enables a biological material to be produced possessing specific characteristics as a result of the invention shall extend to biological material directly obtained through that process and to any other biological material derived from the directly obtained biological material through the propagation or multiplication in an identical or divergent form and possessing those same characteristics."
Novartis argued that Article 8(2) applies to claim 8 of 511 and claim 1 of 777 as they require the production of biological material (defined in Article 2(1)(a) of the Biotech Directive as "any material containing genetic information and capable of reproducing itself or being reproduced in a biological system") in that filamentous phage are required. Filamentous phage display a binding molecule specific for the target and they contain genetic material encoding the binding molecule and hence "have specific characteristics as a result of the invention", as required by Article 8(2). If Article 8 (2) were to apply to the claim therefore, protection would extend only to the phage particle and not to the binding molecule as it was common ground that ranibizumab was not a biological material according to Article 2(1)(a).
MedImmune argued that the claims were methods for producing "a binding molecule specific for a particular target epitope or antigen" (as in claim 8 of 511) or "a molecule with binding specificity for a particular target" (as in claim 1 of 777). They do not enable the production of biological material as a result of the invention as the binding molecules are not "biological materials". Further, the phage particles may become damaged when the nucleic acid encoding the binding molecule is removed, such that they do not possess the required specific characteristics as a result of the invention.
The Judge found that it is to the claims that one must look to determine whether Article 8 (2) applies. In accordance with MedImmune's first argument, as the claims were specifically directed to the production of binding molecules, and these are not biological materials in accordance with the definitions of the Biotech Directive, Article 8(2) does not therefore apply and cannot circumscribe the protection conferred by the claims. MedImmune's second argument was not deemed to be persuasive.
The Judge made further comments as to the potential effect this interpretation would have on, for example Patents for recombinant methods of producing proteins, "since proteins are not "biological materials" within the definition in Article 2(1)(a), yet recombinant methods of producing them involve the production of biological materials" (paragraph [575] ). He further noted that analysis by the Advocate General Jacobs in Case C-377/98 19 was consistent with the purpose of Article 8(2) being not to limit but potentially to extend the protection conferred by process claims in biotechnological Patents.
Summary and Conclusions
The Patents were found to be invalid and not infringed, the Judge finding against MedImmune in respect of priority, obviousness, and infringement. It is noteworthy that the Judge relied heavily on the expert evidence that was available to him, particularly with respect to priority, construction and obviousness. Indeed, the Judge himself noted that the availability of evidence was what had allowed him to reach a different conclusion on obviousness than had previously been reached by the EPO Opposition Division on a related European Patent in which Professor Smith's talk at the Banbury conference had been cited as prior art. This may be relevant when the parallel proceedings in other European countries (reportedly including France, Germany, the Netherlands and Switzerland) are decided, as not all countries deal with expert evidence in the same way as the UK courts. This is perhaps an area where divergence in outcomes may be likely.
As regards the future of this dispute, it has been reported that MedImmune will seek permission to appeal. The judgement also indicates that a further hearing is to be scheduled to hear the question of entitlement of MedImmune to claim priority from PD3. However, in view of the position in the judgement on priority entitlement, it would seem that it would not be possible for the outcome of this hearing to improve MedImmune's position.
MedImmune may face further hurdles. Both 511 and 777 expired in July 2011, but there is an Opposition pending on 777 at the EPO, which was filed by Novartis. The Opposition was filed only relatively recently and the Proceedings are at an early stage; the Patentee having yet to respond in writing to the notice of Opposition. It is thus still possible that the EPO could revoke the 777 patent. Further, any Decision of the Opposition Division may also be appealed. Revocation of 777 by the EPO would have the effect of the Patent being revoked as if it never existed in each of the EPC contracting states in which it has been validated.
It is also interesting to note that (at least in the UK) there is a granted SPC on the 777 patent in respect of ranibizumab which has the effect of extending any protection conferred by the 777 patent in respect of ranibizumab (should it be in force) to 2016. The SPC can itself be challenged.
It can be seen from the above that the ultimate outcome of this dispute is still very uncertain and the final outcome will not be known for some time yet.
The judgement is of interest in view of the useful summaries that the Judge provides in respect of recent UK case law. Of particular interest is the Judge's finding that the process claims (specifically claim 8 of 511 and claim 1 of 777) would be infringed by an antibody that was made according to the claimed processes. The Patents relate to an invention in the field of antibody screening, and contain no claims to antibody products, yet the infringement was alleged in respect of such products, which were alleged to be identified and made using the claimed processes. Although the patents were found to be invalid and also not infringed, there was a clear indication that a product obtained according to a screening process claim could infringe a process claim as the direct product of that process, providing that there is a claim which contains language referring to an appropriate manufacturing step and that the "loss of identity" requirements of Pioneer v Warner are fulfilled.
Screening process claims may thus be powerful tools that allow Patent proprietors effectively secure protection for commercially relevant products that are subsequently identified according to claimed screening processes. This is despite the fact that "reach through" claims are not in general considered by Patent Offices to be allowable (see for example T1063/06 20 ) and claims to "products obtainable by" such processes are now rarely granted, at least by the EPO. To take advantage of such protection there must be a step in at least one claim which effectively transforms the information output of the screening process into a physical or manufactured product, to ensure that any commercial product is directly obtained by the claimed process, as required by section 60(1)(c).
